Mazdutide vs Epithalon
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Epithalon is a synthetic tetrapeptide developed from the pineal gland extract Epithalamin by Russian scientist Dr. Vladimir Khavinson. It is one of the most researched longevity peptides, known for activating telomerase and extending telomere length — the molecular hallmarks of cellular aging.
- Half-Life
- ~7 days
- 2–4 hours
- Admin Route
- SubQ
- SubQ, Sublingual
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 5–10 mg total per cycle
- Frequency
- Once weekly
- 0.5–1 mg daily
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Activates telomerase enzyme, extending telomere length
- May slow cellular and biological aging
- Regulates melatonin production and circadian rhythms
- Improves sleep quality
- Powerful antioxidant properties
- May reduce incidence of age-related diseases
- Supports immune system function
- Studied for cancer prevention properties in animal models
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Injection site irritation (mild)
- Temporary sleep changes during cycle (usually improves)
- Rare: fatigue
- Stacks With
- —
- —